Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
In a recent disclosure to the Securities and Exchange Commission, Brendan B. Springstubb, a director at Evolent Health, Inc. (NYSE:EVH), reported the acquisition of 5,000 shares of the company’s Class A Common Stock. The shares were purchased on March 4, 2025, at a price of $8.75 per share, resulting in a total transaction value of $43,750. The purchase comes as the stock trades near its 52-week low of $8.35, having declined over 74% in the past year.
Additionally, on March 3, 2025, Mr. Springstubb was granted 6,842 restricted stock units under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. These units will vest on the earlier of March 3, 2026, or the date of the company’s 2025 annual meeting, contingent upon his continued service. According to InvestingPro analysis, the company appears undervalued, with analyst price targets ranging from $12 to $20 per share. Subscribers can access 13 additional ProTips and comprehensive analysis for EVH.
Following these transactions, Mr. Springstubb holds a total of 11,842 shares directly in the $1.01 billion market cap healthcare company.
In other recent news, Evolent Health reported its fourth-quarter results, which fell short of analyst expectations. The company posted an adjusted earnings per share of -$0.02, missing the consensus estimate of $0.07, while revenue reached $646.5 million, slightly below the projected $652.2 million. Despite a 16.3% year-over-year revenue increase, Evolent’s guidance for 2025 disappointed investors, with expected revenue between $2.06 billion and $2.11 billion, falling short of the anticipated $2.42 billion. Piper Sandler responded by lowering Evolent Health’s price target to $16 from $17 but maintained an Overweight rating, noting the company’s strong customer retention and value proposition.
Meanwhile, Citizens JMP raised Evolent Health’s stock target to $13, maintaining a Market Outperform rating, citing confidence in the company’s management and strategic measures. The firm acknowledged challenges faced by Evolent Health in 2024 but expressed optimism about the company’s future profitability. Evolent’s management highlighted successful contract amendments and new revenue agreements, which are expected to improve 2025 financial outcomes. Analysts at Piper Sandler also noted the company’s forecasted adjusted EBITDA of $150 million for 2025, considering it well-judged despite recent challenges. These developments reflect a mixed outlook for Evolent Health, with some analysts expressing cautious optimism about its future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.